Kolon Life Science Inc (102940) Fair Value & Analysis
Healthcare · KR · Market cap 630B KRW
Analysis
Kolon Life Science Inc (102940) currently trades at 45,000 KRW, while our model-based Fair Value estimate is 37,195 KRW — implying the stock looks roughly 17.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for anti-cancer and intermediates; and pyrithione antimicrobial for shampoo and soap bars, cosmetic and wet wipes, fabric softeners, metalworking fluids, antifouling paints, and fire-fighters. In addition, it offers Kolon BESFLOC polymer used in chemical, food, leather, pharmaceutical, textile, and dairy industries, as well as in settling reservoirs, sludge thickeners, floating reservoirs, and dehydrators in sewage treatment plants. The company was formerly known as Korea Tissuegene Asia, Ltd. and changed its name to Kolon Life Science Inc. in January 2006. Kolon Life Science Inc. was founded in 20…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.